TY - JOUR AU - Song, X. AU - Cong, Z. AU - Wilson, K. PY - 2016 DA - 2016// TI - Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States JO - Curr Med Res Opin VL - 32 UR - https://doi.org/10.1185/03007995.2015.1105202 DO - 10.1185/03007995.2015.1105202 ID - Song2016 ER - TY - JOUR AU - Alexanian, R. PY - 1969 DA - 1969// TI - Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens JO - JAMA VL - 208 UR - https://doi.org/10.1001/jama.1969.03160090040009 DO - 10.1001/jama.1969.03160090040009 ID - Alexanian1969 ER - TY - JOUR AU - Rajkumar, S. V. AU - Kumar, S. PY - 2016 DA - 2016// TI - Multiple myeloma: diagnosis and treatment JO - Mayo Clin Proc VL - 91 UR - https://doi.org/10.1016/j.mayocp.2015.11.007 DO - 10.1016/j.mayocp.2015.11.007 ID - Rajkumar2016 ER - TY - JOUR AU - Rosinol, L. PY - 2012 DA - 2012// TI - Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-02-408922 DO - 10.1182/blood-2012-02-408922 ID - Rosinol2012 ER - TY - JOUR AU - Johnson, D. C. PY - 2016 DA - 2016// TI - Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms10290 DO - 10.1038/ncomms10290 ID - Johnson2016 ER - TY - JOUR AU - Rajkumar, S. V. PY - 2016 DA - 2016// TI - Myeloma today: disease definitions and treatment advances JO - Am J Hematol VL - 91 UR - https://doi.org/10.1002/ajh.24236 DO - 10.1002/ajh.24236 ID - Rajkumar2016 ER - TY - JOUR AU - Harland, M. PY - 2008 DA - 2008// TI - A comparison of CDKN2A mutation detection within the melanoma genetics consortium (GenoMEL) JO - Eur J Cancer VL - 44 UR - https://doi.org/10.1016/j.ejca.2008.03.005 DO - 10.1016/j.ejca.2008.03.005 ID - Harland2008 ER - TY - JOUR AU - Soufir, N. PY - 1998 DA - 1998// TI - Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French familial melanoma study group JO - Hum Mol Genet VL - 7 UR - https://doi.org/10.1093/hmg/7.2.209 DO - 10.1093/hmg/7.2.209 ID - Soufir1998 ER - TY - JOUR AU - Bishop, D. T. PY - 2002 DA - 2002// TI - Geographical variation in the penetrance of CDKN2A mutations for melanoma JO - J Natl Cancer Inst VL - 94 UR - https://doi.org/10.1093/jnci/94.12.894 DO - 10.1093/jnci/94.12.894 ID - Bishop2002 ER - TY - JOUR AU - Goldstein, A. M. PY - 2007 DA - 2007// TI - Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents JO - J Med Genet VL - 44 UR - https://doi.org/10.1136/jmg.2006.043802 DO - 10.1136/jmg.2006.043802 ID - Goldstein2007 ER - TY - JOUR AU - Fischer, M. PY - 2007 DA - 2007// TI - Analysis of exon 2 of MTS1 in HPV-positive and HPV-negative tumors of the head and neck region JO - Eur Arch Otorhinolaryngol VL - 264 UR - https://doi.org/10.1007/s00405-007-0258-4 DO - 10.1007/s00405-007-0258-4 ID - Fischer2007 ER - TY - JOUR AU - McKenzie, H. A. PY - 2010 DA - 2010// TI - Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A JO - Hum Mutat VL - 31 UR - https://doi.org/10.1002/humu.21245 DO - 10.1002/humu.21245 ID - McKenzie2010 ER - TY - JOUR AU - Dilworth, D. PY - 2000 DA - 2000// TI - Germline CDKN2A mutation implicated in predisposition to multiple myeloma JO - Blood VL - 95 ID - Dilworth2000 ER - TY - JOUR AU - Mukherjee, B. PY - 2012 DA - 2012// TI - Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers JO - J Natl Cancer Inst VL - 104 UR - https://doi.org/10.1093/jnci/djs221 DO - 10.1093/jnci/djs221 ID - Mukherjee2012 ER - TY - JOUR AU - Mitchell, J. S. PY - 2016 DA - 2016// TI - Genome-wide association study identifies multiple susceptibility loci for multiple myeloma JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms12050 DO - 10.1038/ncomms12050 ID - Mitchell2016 ER - TY - JOUR AU - Camp, N. J. AU - Werner, T. L. AU - Cannon-Albright, L. A. PY - 2008 DA - 2008// TI - Familial myeloma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMc081677 DO - 10.1056/NEJMc081677 ID - Camp2008 ER - TY - JOUR AU - Altieri, A. PY - 2006 DA - 2006// TI - Familial risks and temporal incidence trends of multiple myeloma JO - Eur J Cancer VL - 42 UR - https://doi.org/10.1016/j.ejca.2005.11.033 DO - 10.1016/j.ejca.2005.11.033 ID - Altieri2006 ER - TY - JOUR AU - Kristinsson, S. Y. PY - 2009 DA - 2009// TI - Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance JO - Haematologica VL - 94 UR - https://doi.org/10.3324/haematol.2009.006346 DO - 10.3324/haematol.2009.006346 ID - Kristinsson2009 ER - TY - JOUR AU - Lynch, H. T. PY - 2001 DA - 2001// TI - Familial multiple myeloma: a family study and review of the literature JO - J Natl Cancer Inst VL - 93 UR - https://doi.org/10.1093/jnci/93.19.1479 DO - 10.1093/jnci/93.19.1479 ID - Lynch2001 ER - TY - JOUR AU - Zhang, Y. AU - Xiong, Y. PY - 1999 DA - 1999// TI - Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53 JO - Mol Cell VL - 3 UR - https://doi.org/10.1016/S1097-2765(00)80351-2 DO - 10.1016/S1097-2765(00)80351-2 ID - Zhang1999 ER - TY - JOUR AU - Zhang, Y. AU - Xiong, Y. AU - Yarbrough, W. G. PY - 1998 DA - 1998// TI - ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways JO - Cell VL - 92 UR - https://doi.org/10.1016/S0092-8674(00)81401-4 DO - 10.1016/S0092-8674(00)81401-4 ID - Zhang1998 ER - TY - JOUR AU - Lin, Y. C. PY - 2007 DA - 2007// TI - Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression JO - Oncogene VL - 26 UR - https://doi.org/10.1038/sj.onc.1210507 DO - 10.1038/sj.onc.1210507 ID - Lin2007 ER - TY - JOUR AU - Kamijo, T. PY - 1997 DA - 1997// TI - Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF JO - Cell VL - 91 UR - https://doi.org/10.1016/S0092-8674(00)80452-3 DO - 10.1016/S0092-8674(00)80452-3 ID - Kamijo1997 ER - TY - JOUR AU - Borg, A. PY - 1996 DA - 1996// TI - Novel germline p16 mutation in familial malignant melanoma in southern Sweden JO - Cancer Res VL - 56 ID - Borg1996 ER - TY - JOUR AU - Hewitt, C. PY - 2002 DA - 2002// TI - Germline mutation of ARF in a melanoma kindred JO - Hum Mol Genet VL - 11 UR - https://doi.org/10.1093/hmg/11.11.1273 DO - 10.1093/hmg/11.11.1273 ID - Hewitt2002 ER - TY - JOUR AU - Caldas, C. PY - 1994 DA - 1994// TI - Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma JO - Nat Genet VL - 8 UR - https://doi.org/10.1038/ng0994-27 DO - 10.1038/ng0994-27 ID - Caldas1994 ER - TY - JOUR AU - Liu, Q. PY - 1995 DA - 1995// TI - MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines JO - Oncogene VL - 10 ID - Liu1995 ER - TY - JOUR AU - Walker, B. A. PY - 2015 DA - 2015// TI - Mutational Spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.1503 DO - 10.1200/JCO.2014.59.1503 ID - Walker2015 ER - TY - JOUR AU - Simon, M. PY - 2006 DA - 2006// TI - Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas JO - Oncol Rep VL - 16 ID - Simon2006 ER - TY - JOUR AU - Iwadate, Y. PY - 2000 DA - 2000// TI - Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents JO - Int J Oncol VL - 17 ID - Iwadate2000 ER - TY - JOUR AU - Andreeff, M. PY - 2016 DA - 2016// TI - Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-0481 DO - 10.1158/1078-0432.CCR-15-0481 ID - Andreeff2016 ER - TY - JOUR AU - Gu, D. PY - 2014 DA - 2014// TI - Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0103015 DO - 10.1371/journal.pone.0103015 ID - Gu2014 ER - TY - JOUR AU - Reis, B. PY - 2016 DA - 2016// TI - Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts JO - Haematologica VL - 101 UR - https://doi.org/10.3324/haematol.2015.139717 DO - 10.3324/haematol.2015.139717 ID - Reis2016 ER - TY - JOUR AU - Linggi, B. PY - 2002 DA - 2002// TI - The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia JO - Nat Med VL - 8 UR - https://doi.org/10.1038/nm726 DO - 10.1038/nm726 ID - Linggi2002 ER -